Neurobeachin ( neurobeachin (NBEA) ) is a novel gene associated with GLP ‐1 receptor agonist associated weight loss
Authors' conclusion
These findings indicate that NBEA genetic variation is predictive of GLP-1RA weight loss and may support future efforts to identify individuals likely to experience significant weight loss with GLP-1RAs, enabling personalised obesity treatment strategies.
Study context
- Population
- Individuals prescribed a GLP-1 RA in the NIH All of Us and UK BiobankUK Biobank 241
- Comparison
- Responsive or non-responsive NBEA genetic score vs not meeting threshold
- Outcome
- Weight loss response: high responsiveness (top 20th percentile for weight loss) and non-responsiveness (weight change ≥0%)
- Follow-up
- 12-18 months
Methodological detailsdiscovery and validation cohorts
- Discovery and validation cohorts
Performance
As reported in the abstract
High responsiveness with responsive NBEA score, liraglutide
Liraglutide, discovery: 82% more likely to be highly responsive
FDR p = 1.8 × 10-6
Liraglutide, UK Biobank validation
OR = 2.37; p = ·008
Semaglutide, discovery and validation
OR = 1.63 and OR = 2.21 respectively (p < ·05)
Further findings
Non-response with non-responsive NBEA score
- Liraglutide, discovery: 50% more likely to not lose weight
- FDR p = 2.9 × 10-4
- Liraglutide, UK Biobank validation
- OR = 1.81; p = ·041
- Non-response score did not validate for semaglutide
Original publication
Neurobeachin ( NBEA ) is a novel gene associated with GLP ‐1 receptor agonist associated weight loss. Diabetes Obes Metab. Published 18 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →